Mary B Kansora1,2, Raquel Goldhardt3,4. 1. VA North Texas Health Care System, 4500 S. Lancaster Rd, Dallas, TX 75216. 2. The University of Texas Southwestern Medical Center, Department of Ophthalmology, 5323 Harry Hines Blvd., Dallas, TX 75390. 3. Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL 33125. 4. Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, 900 NW 17 Street, Suite 275, Miami, FL. 33136.
Abstract
PURPOSE OF REVIEW: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. RECENT FINDINGS: For many years cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. SUMMARY: Management of PDR requires the identification of high risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.
PURPOSE OF REVIEW: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. RECENT FINDINGS: For many years cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. SUMMARY: Management of PDR requires the identification of high risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.
Authors: David W Hutton; Joshua D Stein; Neil M Bressler; Lee M Jampol; David Browning; Adam R Glassman Journal: JAMA Ophthalmol Date: 2017-06-01 Impact factor: 7.389
Authors: Joseph Googe; Alexander J Brucker; Neil M Bressler; Haijing Qin; Lloyd P Aiello; Andrew Antoszyk; Roy W Beck; Susan B Bressler; Frederick L Ferris; Adam R Glassman; Dennis Marcus; Cynthia R Stockdale Journal: Retina Date: 2011-06 Impact factor: 4.256